Evidence map›Paper›PMID 35881043›Full record

ArticleThe oncologist2022

Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study.

Andrea Necchi, Philippe E Spiess, Marco Bandini, Giuseppe Basile, Petros Grivas, Gennady Bratslavsky, Joseph Jacob, Natalie Danziger, Douglas Lin, Brennan Decker and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Andrea NecchiIRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.ORCID 0000-0002-3007-2756
Philippe E SpiessMoffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-5723-1972
Marco BandiniIRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
Giuseppe BasileIRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy.
Petros GrivasUniversity of Washington, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Gennady BratslavskySUNY Upstate Medical University, Syracuse, NY, USA.
Joseph JacobSUNY Upstate Medical University, Syracuse, NY, USA.
Natalie DanzigerFoundation Medicine, Inc., Cambridge, MA, USA.
Douglas LinFoundation Medicine, Inc., Cambridge, MA, USA.
Brennan DeckerFoundation Medicine, Inc., Cambridge, MA, USA.
Ethan S SokolFoundation Medicine, Inc., Cambridge, MA, USA.
Richard S P HuangFoundation Medicine, Inc., Cambridge, MA, USA.
Sanjay B KulkarniKulkarni Reconstructive Urology Center, Pune, Maharashtra, India.
Jeffrey S RossFoundation Medicine, Inc., Cambridge, MA, USA.
Foundation Medicine (United States)SUNY Upstate Medical University · USVita-Salute San Raffaele University · ITKulkarni reconstructive Urology Center · INMoffitt Cancer Center · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced pelvic squamous cell carcinoma (pSCC) is a broad category of cancers affecting different pelvic organs and usually featuring unfavorable clinical outcomes. Thus, we aimed to assess genomic differences among pSCC cases and learn whether pSCC could potentially benefit from targeted therapies and/or immunotherapy. MATERIALS AND

methodsA total of 1917 advanced pSCCs, including penile (penSCC), male urethral (murthSCC), male anal (manSCC), female urethral (furthSCC), vulvar (vulSCC), cervical (crvSCC), female anal (fanSCC), and vaginal (vagSCC), underwent comprehensive genomic profiling (CGP). We used hybrid capture-based CGP to evaluate recurrent genomic alterations (GAs). Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA and microsatellite instability (MSI) was determined on up to 95 loci. Programmed cell-death-ligand-1 (PD-L1) expression was determined by immunohistochemistry (IHC; Dako 22C3).

resultsPIK3CA was the most frequently identified potentially "actionable" GA (22%-43%), followed by mTOR pathway [PTEN (0%-18%), FBXW7 (7%-29%)], and cell-cycle GAs. DNA-damage response (DDR) GAs and receptor-tyrosine kinase (RTK) targeted options were uncommon. NOTCH1 GAs were present in >15% of penSCC and vulvSCC. TMB ≥10 mut/Mb was >15% in manSCC, fanSCC, crvSCC, and vagSCC. PD-L1 high expression was >18% in all pSCC except urthSCC, manSCC, and vagSCC. HPV-16/18 detection was highest in manSCC, fanSCC, and crvSCC.

conclusionDespite similar histology, pSCCs can differ in GAs and HPV status. Overall, PIK3CA is the most frequent potentially "targetable" GA followed by mTOR and cell cycle pathway. RTK and DDR GAs are rare in pSCC. Immunotherapy could be considered for pSCC management based on TMB and PD-L1 expression.

Indexed as

Carcinoma, Squamous CellUrogenital NeoplasmsB7-H1 AntigenFemaleGenomicsHuman papillomavirus 16Human papillomavirus 18HumansMaleB7-H1 Antigenbiomarkerscomprehensive genomic profilingimmunotherapypelvic cancersquamous cell carcinomatargeted therapy

Identifiers

PMID35881043
PMCPMC10259761
OpenAlexW4288037648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.